KRAS and neoplasm: Moreover, RAS(ON) multi-selective inhibitors could also provide therapeutic benefit in combination with mutant-selective KRAS inhibitors to improve anti-tumour response by blocking adaptive pathway reactivation and preventing escape through emergence of secondary oncogenic RAS or RTK mutations.